CEO Emma Walmsley’s strategy has focussed on vaccines, cancer and infectious diseases and a shift in the company’s HIV focus to long-acting treatment and prevention therapies. The strategy has paid off as GSK gears up for 12 launches from 2025.
Crowley has been appointed to the newly created role of senior VP, growth. The announcement continues the agency’s positive momentum as it solidifies its strong leadership bench.
Lilly said it expects the drugs to remain in tight supply, but plans for significant production increases in the second half of the year.
Known for its innovative approach to scientific storytelling, Enzyme Communications brings a new dimension to Bioscript Group by providing expertise in building scientific stories from data, and helping clients effectively articulate how their products change lives.
The solution designed to enhance patient affordability and medication adherence by reaching the most influential stakeholder in health care – the healthcare professional, who lacks awareness of Patient affordability programs. Co-Pay Spark empowers HCPs to ignite awareness of and access to assistance programs for the patients who need them most, ultimately leading to improved adherence and better health outcomes.
Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s antibody-drug conjugate Tivdak on Monday secured the FDA’s full approval for recurrent or metastatic cervical cancer that had progressed on or after chemotherapy.